BCLI · XBRL financial data
Brainstorm Cell Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BCLI's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 22,329 | 15,235 | 13,956 | 10,746 | 4,651 | 4,175 |
| General and administrative | 9,355 | 9,304 | 10,866 | 10,693 | 7,042 | 5,778 |
| Operating income (loss) | (31,684) | (24,539) | (24,822) | (21,439) | (11,693) | (9,953) |
| Net income (loss) | (31,811) | (24,457) | (24,277) | (17,192) | (11,623) | (10,307) |
| Earnings per share, basic‡ USD per share | (238.36) | (151.48) | (147.03) | (89.11) | (34.48) | (1.11) |
| Earnings per share, diluted‡ USD per share | (238.36) | (151.48) | (147.03) | (89.11) | (34.48) | (1.11) |
| Weighted average shares, basic‡ thousands of shares | 134 | 162 | 164 | 193 | 336 | 9,269 |
| Weighted average shares, diluted‡ thousands of shares | 134 | 162 | 164 | 193 | 336 | 9,269 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2025); filings made before it reported them unadjusted.
- † Share count changed about 25x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (BCLI's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 37,829 | 18,856 | 772 | 1,300 | 187 | 29 |
| Short-term investments | 4,107 | 3,238 | 2,211 | — | — | — |
| Prepaid and other current assets | 1,002 | 1,100 | 32 | 548 | 135 | 192 |
| Total current assets | 43,242 | 23,280 | 3,106 | 1,899 | 385 | 307 |
| Property and equipment, net | 1,119 | 1,189 | 933 | 686 | 434 | 235 |
| Right-of-use asset | 6,872 | 4,781 | 4,389 | 1,416 | 807 | 208 |
| Total assets | 51,259 | 29,277 | 8,451 | 4,208 | 1,832 | 1,022 |
| Accounts payable | 5,417 | 3,700 | 6,224 | 4,954 | 6,080 | 7,067 |
| Accrued liabilities | 1,261 | 83 | 84 | 1,240 | 619 | 396 |
| Total current liabilities | 11,233 | 6,317 | 8,800 | 7,800 | 8,978 | 11,007 |
| Lease liability, non-current | 4,562 | 3,618 | 2,666 | 672 | 171 | — |
| Total liabilities | 15,795 | 9,935 | 11,466 | 9,066 | 9,596 | 11,007 |
| Accumulated deficit | (149,087) | (173,544) | (197,821) | (215,013) | (226,636) | (236,943) |
| Total stockholders' equity | 35,464 | 19,342 | (3,015) | (4,858) | (7,764) | (9,985) |
| Total liabilities and equity | 51,259 | 29,277 | 8,451 | 4,208 | 1,832 | 1,022 |
| Common shares outstanding (cover page)‡ thousands of shares | 160 | 164 | 165 | 307 | 437 | 11,035 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2025); filings made before it reported them unadjusted.
- † Share count changed about 25x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (BCLI's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (31,811) | (24,457) | (24,277) | (17,192) | (11,623) | (10,307) |
| Stock-based compensation | 2,560 | 1,366 | 1,682 | 1,490 | 750 | 1,520 |
| Net cash from operating activities | (35,193) | (26,265) | (19,320) | (20,458) | (9,093) | (6,975) |
| Purchases of property and equipment | 378 | 330 | 29 | 18 | — | — |
| Net cash from investing activities | (4,452) | 323 | 998 | 2,193 | 12 | — |
| Proceeds from issuing common stock | 143 | 151 | 151 | 171 | 180,000 | 186,000 |
| Share repurchases | 116 | — | — | — | — | — |
| Net cash from financing activities | 76,938 | 6,969 | 238 | 18,978 | 7,967 | 6,880 |
| Net change in cash | 37,293 | (18,973) | (18,084) | 713 | (1,114) | (95) |
- † Share count changed about 25x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics | 22 | not reported | (895) | 11.0M | 0.0 quarters | 10-QJun 30, 2026 |
| Kiora Pharmaceuticals | 7,077 | not reported | (1,892)* | 4.4M | 8.9 quarters | 10-QJun 30, 2026 |
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| Palisade Bio | 125,172 | 500 | (7,603)* | 174.3M | 16.5 quarters | 10-QJun 30, 2026 |
| Phio Pharmaceuticals | 12,996 | not reported | (4,035)* | 11.6M | 3.2 quarters | 10-QJun 30, 2026 |
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.